We are live on ! Find out more
STSA

Satsuma Pharmaceuticals, Inc. Common Stock
STSA

Delisted

STSA was delisted on the 7th of June, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of STSA yet.

STSA Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q2 2023, worth a combined $0 — down 100% from $12.7M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of STSA and 0 opened new positions — a net loss of 31 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BML Capital Management, exiting entirely with an estimated $4.5M sold.

  • 0 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q2 2023, down from 31 in Q1 2023.
  • Funds reported $0 of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 31 closed out, a net change of -31 holders.
  • The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was BML Capital Management, an estimated $4.5M sold.

Based on aggregated 13F filings for Q2 2023.